2012
Identification of FoxM1 As Therapeutic Target in TKI-Resistant Ph+ ALL
Buchner M, Klemm L, Zhengshan C, Geng H, Muschen M. Identification of FoxM1 As Therapeutic Target in TKI-Resistant Ph+ ALL. Blood 2012, 120: 874. DOI: 10.1182/blood.v120.21.874.874.Peer-Reviewed Original ResearchB cell precursorsLymphoblastic leukemiaTherapeutic targetPhiladelphia chromosome-positive acute lymphoblastic leukemiaPositive acute lymphoblastic leukemiaARF peptidesCell precursorsTreatment of TKIMajority of patientsTime of diagnosisAcute lymphoblastic leukemiaPatient-derived xenograftsValid therapeutic targetEffects of TKIsPotential therapeutic agentForkhead box transcription factor familyCell cycleSuperoxide dismutase expressionG0/G1Thiostrepton treatmentTKI treatmentPoor outcomeCombination therapyFl miceClinical trialsYM155 sensitivity in pediatric acute lymphoblastic leukemia.
Chang B, Jemal A, Tyner J, Thayer M, Muschen M, Druker B. YM155 sensitivity in pediatric acute lymphoblastic leukemia. Journal Of Clinical Oncology 2012, 30: 9555-9555. DOI: 10.1200/jco.2012.30.15_suppl.9555.Peer-Reviewed Original ResearchPediatric acute lymphoblastic leukemiaAcute lymphoblastic leukemiaLymphoblastic leukemiaPhase I/II studyNCI standard riskStandard intensive chemotherapyProtein expressionSubset of patientsAdditional therapeutic agentsB-cell malignanciesYM155 treatmentIntensive chemotherapyII studyPhospho-flow cytometryPrimary patientsCombination therapyAnnexin V bindingTarget effectsNovel agentsPossible efficacyHigh riskStandard riskIsobologram analysisMultiple protein expressionMalignant cells
2011
Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia
Jemal A, Tyner J, Thayer M, Muschen M, Druker B, Chang B. Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia. Blood 2011, 118: 2490. DOI: 10.1182/blood.v118.21.2490.2490.Peer-Reviewed Original ResearchPediatric acute lymphoblastic leukemiaAcute lymphoblastic leukemiaLymphoblastic leukemiaPatient samplesPrimary patientsCell linesActivation of apoptosisPediatric B-cell precursorHematopoietic stem cell transplantSelective survivin suppressantStandard intensive chemotherapyEarly phase I studiesSubset of patientsStem cell transplantPhase I studiesCommon pediatric malignancyB-cell malignanciesPrimary patient samplesB cell precursorsLymphoblastic cell linesAdditional therapyIntensive chemotherapyCell transplantCombination therapyPediatric malignancies